Report cover image

Nuclear Medicine & Radiopharmaceuticals Industry Research Report 2025

Publisher APO Research, Inc.
Published Jul 16, 2025
Length 121 Pages
SKU # APRC20261789

Description

Summary

According to APO Research, the global Nuclear Medicine & Radiopharmaceuticals market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Nuclear Medicine & Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Nuclear Medicine & Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Nuclear Medicine & Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Nuclear Medicine & Radiopharmaceuticals include Aurobindo Pharma, Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, Mundipharma and SIEMENS, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Nuclear Medicine & Radiopharmaceuticals, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nuclear Medicine & Radiopharmaceuticals.

The report will help the Nuclear Medicine & Radiopharmaceuticals manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.



The Nuclear Medicine & Radiopharmaceuticals market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Nuclear Medicine & Radiopharmaceuticals market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Nuclear Medicine & Radiopharmaceuticals Segment by Company

Aurobindo Pharma
Bracco Imaging
Cardinal Health
Curium Pharma
GE Healthcare
Jubilant Pharma
Lantheus
Mundipharma
SIEMENS
Bayer
Dongcheng
Eli Lilly
Novartis
China Isotope & Radiation
Nuclear Medicine & Radiopharmaceuticals Segment by Type

Diagnostic Radiopharmaceuticals
Therapeutic Radiopharmaceuticals
Nuclear Medicine & Radiopharmaceuticals Segment by Application

Oncology
Cardiology
Thyroid
Others
Nuclear Medicine & Radiopharmaceuticals Segment by Region


North America
United States
Canada
Europe

Germany
France
U.K.
Italy
Netherlands
Asia-Pacific

China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico
Brazil
Argentina
Middle East & Africa

Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Medicine & Radiopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nuclear Medicine & Radiopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Medicine & Radiopharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Nuclear Medicine & Radiopharmaceuticals manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Nuclear Medicine & Radiopharmaceuticals by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Nuclear Medicine & Radiopharmaceuticals in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

121 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Nuclear Medicine & Radiopharmaceuticals Market Size (2020-2031)
2.2.2 Global Nuclear Medicine & Radiopharmaceuticals Sales (2020-2031)
2.2.3 Global Nuclear Medicine & Radiopharmaceuticals Market Average Price (2020-2031)
2.3 Nuclear Medicine & Radiopharmaceuticals by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Diagnostic Radiopharmaceuticals
2.3.3 Therapeutic Radiopharmaceuticals
2.4 Nuclear Medicine & Radiopharmaceuticals by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Oncology
2.4.3 Cardiology
2.4.4 Thyroid
2.4.5 Others
3 Market Competitive Landscape by Manufacturers
3.1 Global Nuclear Medicine & Radiopharmaceuticals Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Nuclear Medicine & Radiopharmaceuticals Sales (K Units) of Manufacturers (2020-2025)
3.3 Global Nuclear Medicine & Radiopharmaceuticals Revenue of Manufacturers (2020-2025)
3.4 Global Nuclear Medicine & Radiopharmaceuticals Average Price by Manufacturers (2020-2025)
3.5 Global Nuclear Medicine & Radiopharmaceuticals Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Nuclear Medicine & Radiopharmaceuticals, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Nuclear Medicine & Radiopharmaceuticals, Product Type & Application
3.8 Global Manufacturers of Nuclear Medicine & Radiopharmaceuticals, Established Date
3.9 Global Nuclear Medicine & Radiopharmaceuticals Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Aurobindo Pharma
4.1.1 Aurobindo Pharma Company Information
4.1.2 Aurobindo Pharma Business Overview
4.1.3 Aurobindo Pharma Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Aurobindo Pharma Nuclear Medicine & Radiopharmaceuticals Product Portfolio
4.1.5 Aurobindo Pharma Recent Developments
4.2 Bracco Imaging
4.2.1 Bracco Imaging Company Information
4.2.2 Bracco Imaging Business Overview
4.2.3 Bracco Imaging Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Bracco Imaging Nuclear Medicine & Radiopharmaceuticals Product Portfolio
4.2.5 Bracco Imaging Recent Developments
4.3 Cardinal Health
4.3.1 Cardinal Health Company Information
4.3.2 Cardinal Health Business Overview
4.3.3 Cardinal Health Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Cardinal Health Nuclear Medicine & Radiopharmaceuticals Product Portfolio
4.3.5 Cardinal Health Recent Developments
4.4 Curium Pharma
4.4.1 Curium Pharma Company Information
4.4.2 Curium Pharma Business Overview
4.4.3 Curium Pharma Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Curium Pharma Nuclear Medicine & Radiopharmaceuticals Product Portfolio
4.4.5 Curium Pharma Recent Developments
4.5 GE Healthcare
4.5.1 GE Healthcare Company Information
4.5.2 GE Healthcare Business Overview
4.5.3 GE Healthcare Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
4.5.4 GE Healthcare Nuclear Medicine & Radiopharmaceuticals Product Portfolio
4.5.5 GE Healthcare Recent Developments
4.6 Jubilant Pharma
4.6.1 Jubilant Pharma Company Information
4.6.2 Jubilant Pharma Business Overview
4.6.3 Jubilant Pharma Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Jubilant Pharma Nuclear Medicine & Radiopharmaceuticals Product Portfolio
4.6.5 Jubilant Pharma Recent Developments
4.7 Lantheus
4.7.1 Lantheus Company Information
4.7.2 Lantheus Business Overview
4.7.3 Lantheus Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Lantheus Nuclear Medicine & Radiopharmaceuticals Product Portfolio
4.7.5 Lantheus Recent Developments
4.8 Mundipharma
4.8.1 Mundipharma Company Information
4.8.2 Mundipharma Business Overview
4.8.3 Mundipharma Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Mundipharma Nuclear Medicine & Radiopharmaceuticals Product Portfolio
4.8.5 Mundipharma Recent Developments
4.9 SIEMENS
4.9.1 SIEMENS Company Information
4.9.2 SIEMENS Business Overview
4.9.3 SIEMENS Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
4.9.4 SIEMENS Nuclear Medicine & Radiopharmaceuticals Product Portfolio
4.9.5 SIEMENS Recent Developments
4.10 Bayer
4.10.1 Bayer Company Information
4.10.2 Bayer Business Overview
4.10.3 Bayer Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Bayer Nuclear Medicine & Radiopharmaceuticals Product Portfolio
4.10.5 Bayer Recent Developments
4.11 Dongcheng
4.11.1 Dongcheng Company Information
4.11.2 Dongcheng Business Overview
4.11.3 Dongcheng Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Dongcheng Nuclear Medicine & Radiopharmaceuticals Product Portfolio
4.11.5 Dongcheng Recent Developments
4.12 Eli Lilly
4.12.1 Eli Lilly Company Information
4.12.2 Eli Lilly Business Overview
4.12.3 Eli Lilly Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
4.12.4 Eli Lilly Nuclear Medicine & Radiopharmaceuticals Product Portfolio
4.12.5 Eli Lilly Recent Developments
4.13 Novartis
4.13.1 Novartis Company Information
4.13.2 Novartis Business Overview
4.13.3 Novartis Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
4.13.4 Novartis Nuclear Medicine & Radiopharmaceuticals Product Portfolio
4.13.5 Novartis Recent Developments
4.14 China Isotope & Radiation
4.14.1 China Isotope & Radiation Company Information
4.14.2 China Isotope & Radiation Business Overview
4.14.3 China Isotope & Radiation Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
4.14.4 China Isotope & Radiation Nuclear Medicine & Radiopharmaceuticals Product Portfolio
4.14.5 China Isotope & Radiation Recent Developments
5 Global Nuclear Medicine & Radiopharmaceuticals Market Scenario by Region
5.1 Global Nuclear Medicine & Radiopharmaceuticals Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Nuclear Medicine & Radiopharmaceuticals Sales by Region: 2020-2031
5.2.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Region: 2020-2025
5.2.2 Global Nuclear Medicine & Radiopharmaceuticals Sales by Region: 2026-2031
5.3 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Region: 2020-2031
5.3.1 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Region: 2020-2025
5.3.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Region: 2026-2031
5.4 North America Nuclear Medicine & Radiopharmaceuticals Market Facts & Figures by Country
5.4.1 North America Nuclear Medicine & Radiopharmaceuticals Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Nuclear Medicine & Radiopharmaceuticals Sales by Country (2020-2031)
5.4.3 North America Nuclear Medicine & Radiopharmaceuticals Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.5 Europe Nuclear Medicine & Radiopharmaceuticals Market Facts & Figures by Country
5.5.1 Europe Nuclear Medicine & Radiopharmaceuticals Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Nuclear Medicine & Radiopharmaceuticals Sales by Country (2020-2031)
5.5.3 Europe Nuclear Medicine & Radiopharmaceuticals Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.6 Asia Pacific Nuclear Medicine & Radiopharmaceuticals Market Facts & Figures by Country
5.6.1 Asia Pacific Nuclear Medicine & Radiopharmaceuticals Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Nuclear Medicine & Radiopharmaceuticals Sales by Country (2020-2031)
5.6.3 Asia Pacific Nuclear Medicine & Radiopharmaceuticals Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Nuclear Medicine & Radiopharmaceuticals Market Facts & Figures by Country
5.7.1 South America Nuclear Medicine & Radiopharmaceuticals Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Nuclear Medicine & Radiopharmaceuticals Sales by Country (2020-2031)
5.7.3 South America Nuclear Medicine & Radiopharmaceuticals Revenue by Country (2020-2031)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Market Facts & Figures by Country
5.8.1 Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Sales by Country (2020-2031)
5.8.3 Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Revenue by Country (2020-2031)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Type (2020-2031)
6.1.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Type (2020-2031) & (K Units)
6.1.2 Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Type (2020-2031)
6.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Type (2020-2031)
6.2.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Type (2020-2031)
6.3 Global Nuclear Medicine & Radiopharmaceuticals Price by Type (2020-2031)
7 Segment by Application
7.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Application (2020-2031)
7.1.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Application (2020-2031) & (K Units)
7.1.2 Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Application (2020-2031)
7.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Application (2020-2031)
7.2.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Application (2020-2031)
7.3 Global Nuclear Medicine & Radiopharmaceuticals Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Nuclear Medicine & Radiopharmaceuticals Value Chain Analysis
8.1.1 Nuclear Medicine & Radiopharmaceuticals Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Nuclear Medicine & Radiopharmaceuticals Production Mode & Process
8.2 Nuclear Medicine & Radiopharmaceuticals Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Nuclear Medicine & Radiopharmaceuticals Distributors
8.2.3 Nuclear Medicine & Radiopharmaceuticals Customers
9 Global Nuclear Medicine & Radiopharmaceuticals Analyzing Market Dynamics
9.1 Nuclear Medicine & Radiopharmaceuticals Industry Trends
9.2 Nuclear Medicine & Radiopharmaceuticals Industry Drivers
9.3 Nuclear Medicine & Radiopharmaceuticals Industry Opportunities and Challenges
9.4 Nuclear Medicine & Radiopharmaceuticals Industry Restraints
10 Report Conclusion
11 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.